iQure Pharma
iQure Pharma is a clinical-stage biotech developing first-in-class astrocyte-targeted EAAT2 modulators to treat CNS disorders, with lead asset iQ-007 in Phase 1 for treatment-resistant epilepsy and expansion plans for Parkinson's disease, migraine, and ALS.
- Company typePrivate
- Founded2019
- HeadquartersWilmington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What iQure Pharma does
iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in central nervous system (CNS) disorders. The company's science is centered on EAAT2 (excitatory amino acid transporter 2), the main astrocytic transporter responsible for clearing excess synaptic glutamate, with the goal of breaking the excitotoxicity feedback loop that drives neuronal dysfunction across epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset, iQ-007, is a first-in-class, orally available EAAT2 positive allosteric modulator currently in early clinical development (Phase 1 in treatment-resistant epilepsy, with Phase 2 proof-of-concept preparation underway); a second preclinical program, iQ-008, targets neuropathic pain and neurodegenerative disease.
The company was founded in 2019 and is headquartered in Princeton, New Jersey (incorporated in Delaware), operating with a small team of 1-10 employees. Its platform is grounded in peer-reviewed research published in Annals of Neurology in collaboration with Harvard Medical School, NIH, Boston Children's Hospital, and Jagiellonian University, where Prof. Krzysztof Kaminski — the inventor of iQ-007 — is based. iQure has secured composition-of-matter patent protection for iQ-007 in the United States (granted 2025) and has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (announced June 2026), with Atuka Inc. as a preclinical collaboration partner. Additional academic partnerships include the University of Padova (Dr. Laura Civiero) for mechanistic and patient-stratification work.
iQure is pre-revenue and follows a licensing/royalty-oriented business model typical of clinical-stage biotechs: it has no commercial products, no disclosed pricing, and expects eventual monetization through partnership deals or product commercialization. To date the company has raised approximately $5 million-plus across multiple funding rounds from 2020 through 2026, including a Series A early closing led by Keiretsu Mid-Atlantic (over $600K in 2022), $1.2 million from Ventura BioMed Investors and OKG Capital (2023), and several SEC-registered exempt securities offerings combining debt and equity. Non-dilutive funding has come from NIH programs and The Michael J. Fox Foundation. Its go-to-market motion is centered on scientific publication, conference partnering (BIO International, JPM Week, Biotech Showcase), and direct engagement with pharmaceutical partners and investors.
iQure Pharma firmographics
Firmographics- Name
- iQure Pharma
- Legal name
- iQure Pharma Inc.
- Website
- https://www.iqurepharma.com/
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- iQure Pharma is a clinical-stage biotech developing first-in-class astrocyte-targeted EAAT2 modulators to treat CNS disorders, with lead asset iQ-007 in Phase 1 for treatment-resistant epilepsy and expansion plans for Parkinson's disease, migraine, and ALS.
- Ownership category
- akta.pro rank
iQure Pharma industry classification
Industry- Product category
- CNS Therapeutics
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where iQure Pharma is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
iQure Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Licensing: Pre-revenue clinical-stage biotech company developing CNS therapeutics. Revenue expected from licensing deals, partnerships, or eventual product commercialization.
Go-to-market motion1 record
Marketing channels4 records
iQure Pharma product offering
Product offeringCore offering
iQure Pharma is a clinical-stage biotech company developing first-in-class, orally available small-molecule EAAT2 positive allosteric modulators designed to restore astrocytic glutamate uptake and break the cycle of excitotoxicity in central nervous system disorders. Its lead asset iQ-007 is in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven pipeline expansion into Parkinson's disease, migraine, and ALS, and a second preclinical asset iQ-008 targeting neuropathic pain and neurodegenerative diseases.
Product overview
iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in CNS disorders. The company's science targets EAAT2, the main astrocytic glutamate transporter, to break the cycle of excitotoxicity. The core product is iQ-007, an orally available EAAT2 positive allosteric modulator currently in early clinical development for epilepsy, with expansion strategies for Parkinson's disease, migraine, and ALS. The pipeline includes iQ-007 as the lead asset in clinical development and iQ-008 in preclinical development for neuropathic pain and neurodegenerative diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- iQ-007 First-in-class, orally available EAAT2 positive allosteric modulator designed to restore astrocytic glutamate uptake and break the excitotoxicity cycle. Currently in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven expansion strategies into Parkinson's disease, migraine, and ALS.
- iQ-008 Preclinical-stage therapeutic program targeting neuropathic pain, epilepsy, and neurodegenerative diseases through EAAT2 modulation.
Quantifiable outcome
- Strong preclinical efficacy demonstrated across Parkinson's disease, epilepsy, and migraine models
- +1 more outcomes
Companies that use iQure Pharma
Customer profileSegments1 record
Ideal customer profiles3 records
iQure Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
iQure Pharma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered supporting and core.
- Atuka Inc.supportingCollaboration partner with iQure Pharma on the EAAT2 modulator program for Parkinson's disease, working on preclinical studies across multiple disease-relevant models.
- University of PadovacoreResearch collaboration with Associate Professor Laura Civiero from the University of Padova focusing on iQ-007 targeting EAAT2 to further elucidate its underlying mechanism of action. The collaboration aims to better identify and stratify patients who could benefit from this novel astrocyte-targeted therapy while providing deeper insight into molecular pathways governing glutamate uptake.
- Harvard Medical SchoolcoreResearch collaboration supporting peer-reviewed research validating EAAT2 mechanism as a novel antiseizure strategy. Published in Annals of Neurology.
- Boston Children's HospitalsupportingResearch collaboration supporting peer-reviewed research validating EAAT2 mechanism as a novel antiseizure strategy. Published in Annals of Neurology.
- Jagiellonian UniversitycoreCo-author of peer-reviewed research published in Annals of Neurology validating EAAT2 mechanism as novel antiseizure strategy. Home of Prof. Krzysztof Kaminski, iQ-007 inventor.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
iQure Pharma competitors and assessment
Company assessmentDirect peers
- Ovid Therapeutics: Clinical-stage biopharmaceutical company developing medicines for rare neurological and CNS disorders. Comparable as a small-cap CNS biotech pursuing novel mechanisms in neurology.
- Praxis Precision Medicines: Clinical-stage CNS biotech developing therapies for epilepsy and other central nervous system disorders. Directly comparable as a similarly staged neurology-focused company pursuing novel CNS mechanisms with a small-cap, pipeline-driven profile.
- Longboard Pharmaceuticals: Clinical-stage CNS company developing treatments for neurological conditions including epilepsy. Comparable as a focused CNS clinical-stage biotech with similar indication overlap and small-cap profile.
- Xenon Pharmaceuticals: Clinical-stage CNS biopharmaceutical company with a focus on epilepsy and other neurological conditions. Directly comparable as a CNS-focused clinical biotech with active epilepsy pipeline assets.
- Engrail Therapeutics: Clinical-stage neuroscience company developing therapeutics for CNS disorders including epilepsy and neurodegenerative diseases. Comparable in stage, CNS focus, and small-team biotech execution model.
- Addex Therapeutics: Clinical-stage biopharmaceutical company specializing in allosteric modulators for CNS disorders. Closely aligned with iQure's allosteric-modulator approach to CNS targets and similar small-cap development profile.
Broad incumbents
- UCB: Global biopharmaceutical company with a leading CNS/epilepsy franchise (Vimpat, Briviact, Fintepla). Major incumbent in the treatment-resistant epilepsy space iQure is pursuing.
- SK Biopharmaceuticals: Global biopharmaceutical company focused on CNS therapies including the antiseizure medication Xcopri. Broader incumbent competing in the same epilepsy market iQ-007 is targeting.
- Jazz Pharmaceuticals: Specialty pharmaceutical company with a significant CNS franchise including epilepsy products (e.g., Epidiolex). Larger incumbent operating across overlapping CNS indications with established commercialization channels.
- Sage Therapeutics: CNS-focused biopharmaceutical company (now part of Biogen) with approved neurology assets. Broader incumbent operating in overlapping CNS space with much greater capital, scale, and commercialization infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
iQure Pharma social profiles
Digital presenceiQure Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
iQure Pharma leadership team
Management profileNumber of profiles
Profiles3 records
iQure Pharma funding detail
Funding detailFunding overview
Funding rounds10 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iQure Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iQure Pharma
What does iQure Pharma do?
iQure Pharma is a clinical-stage biotech company developing first-in-class, orally available small-molecule EAAT2 positive allosteric modulators designed to restore astrocytic glutamate uptake and break the cycle of excitotoxicity in central nervous system disorders. Its lead asset iQ-007 is in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven pipeline expansion into Parkinson's disease, migraine, and ALS, and a second preclinical asset iQ-008 targeting neuropathic pain and neurodegenerative diseases.
Is iQure Pharma a public or private company?
iQure Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was iQure Pharma founded?
iQure Pharma was founded in 2019. It employs 1 to 10 people.
Where is iQure Pharma based?
iQure Pharma is headquartered in Wilmington, United States, in the North America region.
How does iQure Pharma make money?
One revenue line is on record: drug Development and Licensing.
Who are iQure Pharma's main competitors?
Direct peers on record are Ovid Therapeutics, Praxis Precision Medicines, Longboard Pharmaceuticals, Xenon Pharmaceuticals, Engrail Therapeutics and Addex Therapeutics. Broad incumbents are UCB, SK Biopharmaceuticals, Jazz Pharmaceuticals and Sage Therapeutics.
Does iQure Pharma have an API?
No public API is recorded for iQure Pharma.
What industry is iQure Pharma in?
iQure Pharma's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 33451 and its SIC code is 2834.